• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迟发性和早发性复发缓解型多发性硬化症:来自回顾性长期随访研究的证据。

Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.

机构信息

Department G. F. Ingrassia, MS Center University of Catania, Catania, Italy.

出版信息

Eur J Neurol. 2018 Dec;25(12):1425-1431. doi: 10.1111/ene.13745. Epub 2018 Aug 3.

DOI:10.1111/ene.13745
PMID:29956427
Abstract

BACKGROUND AND PURPOSE

Late-onset multiple sclerosis (MS) has a prevalence of about 10-20% in natural history MS studies. Few data have been published about the long-term disease trajectory in the cohort of late-onset relapsing-remitting MS (LORRMS). The aim of this study was to identify the risk factors for reaching an Expanded Disability Status Scale (EDSS) score of 6.0 in LORRMS (onset at >40 years of age) and young-onset relapsing-remitting MS (YORRMS) (onset between 18 and 40 years of age).

METHODS

Clinical and radiological [magnetic resonance imaging (MRI) of the brain] follow-up data were collected. Disability was assessed by EDSS score. A Cox proportional hazards model was used to evaluate the demographic and clinical predictors of reaching an EDSS score of 6.0 in the two cohorts.

RESULTS

A total of 671 patients with relapsing-remitting MS were enrolled, 143 (21.3%) with LORRMS and 528 (78.7%) with YORRMS. In LORRMS, age at onset was 47.8 ± 5.3 (mean ± SD) years and duration of follow-up was 120.7 ± 52.7 months. In YORRMS, age at onset was 27 ± 2.7 years and duration of follow-up was 149.9 ± 92.7 months. The survival curve analyses showed a higher probability of reaching an EDSS score of 6.0 for LORRMS in a shorter time (months) than for YORRMS (94.2 vs. 103.2 months; log-rank 8.8; P < 0.05). On MRI, YORRMS showed more brain inflammatory features than LORRMS. In the multivariate Cox model, age at onset [Exp(B) value, 6.5; 95% confidence interval, 1.9-22.6; P < 0.001] and male gender [Exp(B) value, 1.7; 95% confidence interval, 1.0-2.8; P < 0.05] were the strongest predictors of reaching an EDSS score of 6.0.

CONCLUSIONS

The male population with LORRMS reached severe disability faster than those with YORRMS, even when YORRMS showed more brain inflammatory features on MRI.

摘要

背景与目的

在自然病史 MS 研究中,迟发性多发性硬化症(MS)的患病率约为 10-20%。关于迟发性复发缓解型 MS(LORRMS)队列的长期疾病轨迹,发表的数据很少。本研究旨在确定在迟发性复发缓解型 MS(发病年龄>40 岁)和年轻发病型复发缓解型 MS(YORRMS)(发病年龄 18-40 岁)中达到扩展残疾状态量表(EDSS)评分 6.0 的风险因素。

方法

收集临床和放射学(脑部磁共振成像 [MRI])随访数据。残疾程度通过 EDSS 评分进行评估。使用 Cox 比例风险模型评估两个队列中达到 EDSS 评分 6.0 的人口统计学和临床预测因素。

结果

共纳入 671 例复发缓解型 MS 患者,其中 143 例(21.3%)为 LORRMS,528 例(78.7%)为 YORRMS。在 LORRMS 中,发病年龄为 47.8±5.3(均值±标准差)岁,随访时间为 120.7±52.7 个月。在 YORRMS 中,发病年龄为 27±2.7 岁,随访时间为 149.9±92.7 个月。生存曲线分析显示,LORRMS 达到 EDSS 评分 6.0 的概率更高,时间(月)更短,而 YORRMS 则更长(94.2 与 103.2 个月;对数秩检验 8.8;P<0.05)。在 MRI 上,YORRMS 显示出比 LORRMS 更多的脑炎症特征。在多变量 Cox 模型中,发病年龄[Exp(B)值,6.5;95%置信区间,1.9-22.6;P<0.001]和男性性别[Exp(B)值,1.7;95%置信区间,1.0-2.8;P<0.05]是达到 EDSS 评分 6.0 的最强预测因素。

结论

与 YORRMS 相比,LORRMS 中的男性人群更快达到严重残疾,即使 YORRMS 在 MRI 上显示出更多的脑炎症特征。

相似文献

1
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.迟发性和早发性复发缓解型多发性硬化症:来自回顾性长期随访研究的证据。
Eur J Neurol. 2018 Dec;25(12):1425-1431. doi: 10.1111/ene.13745. Epub 2018 Aug 3.
2
Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.使用多水平模型对复发缓解型多发性硬化症的疾病进展进行建模,该模型应用于来自两个自然史队列和一个治疗队列的纵向数据。
Health Technol Assess. 2016 Oct;20(81):1-48. doi: 10.3310/hta20810.
3
Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?晚发型与早发型多发性硬化症患者达到扩展残疾状态量表(EDSS)6.0的时间更快吗?
PLoS One. 2016 Nov 1;11(11):e0165846. doi: 10.1371/journal.pone.0165846. eCollection 2016.
4
Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.非清髓性造血干细胞移植与复发性缓解型多发性硬化患者神经功能障碍的关联。
JAMA. 2015 Jan 20;313(3):275-84. doi: 10.1001/jama.2014.17986.
5
Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis.用于预测复发缓解型多发性硬化病程的纵向残疾曲线
Mult Scler. 2003 Oct;9(5):486-91. doi: 10.1191/1352458503ms945oa.
6
Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.近几十年来多发性硬化症达到残疾里程碑风险的变化:瑞典一项全国范围内基于人群的队列研究。
JAMA Neurol. 2019 Jun 1;76(6):665-671. doi: 10.1001/jamaneurol.2019.0330.
7
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.干扰素β治疗与复发缓解型多发性硬化患者残疾进展的相关性。
JAMA. 2012 Jul 18;308(3):247-56. doi: 10.1001/jama.2012.7625.
8
Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.早发性多发性硬化症与发病年龄对多发性硬化症神经残疾的影响。
Clin Neurol Neurosurg. 2023 Jan;224:107528. doi: 10.1016/j.clineuro.2022.107528. Epub 2022 Nov 23.
9
Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症患者的磁化传递磁共振成像与临床变化
Arch Neurol. 2006 May;63(5):736-40. doi: 10.1001/archneur.63.5.736.
10
Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis.早发型和晚发型多发性硬化与成人型多发性硬化的临床特征及残疾进展比较
J Clin Med. 2020 May 2;9(5):1326. doi: 10.3390/jcm9051326.

引用本文的文献

1
Multiple Sclerosis After the Age of 50 Years: A Comparative Analysis of Late Onset and Adult Onset.50岁之后的多发性硬化症:迟发性与成人发病型的比较分析
J Clin Neurol. 2025 May;21(3):201-212. doi: 10.3988/jcn.2024.0302.
2
Identifying Cladribine prescription pattern in MS: an Italian multicentre study.确定多发性硬化症中克拉屈滨的处方模式:一项意大利多中心研究。
Ther Adv Neurol Disord. 2025 Jan 8;18:17562864241304212. doi: 10.1177/17562864241304212. eCollection 2025.
3
The ageing central nervous system in multiple sclerosis: the imaging perspective.
多发性硬化症的中枢神经系统老化:影像学视角。
Brain. 2024 Nov 4;147(11):3665-3680. doi: 10.1093/brain/awae251.
4
Digital Pathology Identifies Associations between Tissue Inflammatory Biomarkers and Multiple Sclerosis Outcomes.数字病理学鉴定出组织炎症生物标志物与多发性硬化症结果之间的关联。
Cells. 2024 Jun 11;13(12):1020. doi: 10.3390/cells13121020.
5
Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.50岁以上多发性硬化症患者临床复发与疾病转归的关联
Neurology. 2024 Jul 23;103(2):e209574. doi: 10.1212/WNL.0000000000209574. Epub 2024 Jun 13.
6
Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.迟发性多发性硬化症:意大利多发性硬化症注册研究中复发缓解型患者的残疾轨迹。
J Neurol. 2024 Apr;271(4):1630-1637. doi: 10.1007/s00415-023-12152-9. Epub 2024 Jan 3.
7
Late-onset stiff-person syndrome: challenges in diagnosis and management.迟发性僵人综合征:诊断与管理中的挑战
Ther Adv Neurol Disord. 2023 Dec 25;16:17562864231214315. doi: 10.1177/17562864231214315. eCollection 2023.
8
Methyl-CpG-Binding Protein 2 Emerges as a Central Player in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.甲基化 CpG 结合蛋白 2 在多发性硬化症和视神经脊髓炎谱系疾病中崭露头角,成为核心参与者。
Cell Mol Neurobiol. 2023 Nov;43(8):4071-4101. doi: 10.1007/s10571-023-01432-7. Epub 2023 Nov 13.
9
Clinical and Epidemiological Aspects of Late Onset Multiple Sclerosis in East-Azerbaijan, Iran; A Population-Based Study.伊朗东阿塞拜疆省迟发性多发性硬化的临床和流行病学特征:一项基于人群的研究。
Arch Iran Med. 2022 Nov 1;25(11):725-729. doi: 10.34172/aim.2022.114.
10
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review.多发性硬化症中的人格特质与疲劳:一项叙述性综述
J Clin Med. 2023 Jul 6;12(13):4518. doi: 10.3390/jcm12134518.